Straits Times Index
3,275.08 -24.96 (-0.76%) Nikkei
38,382.03 -453.07 (-1.17%) Hang Seng
18,529.32 +49.95 (+0.27%) FTSE 100
8,313.67 +100.18 (+1.22%) Bitcoin USD
62,705.30 -1,057.13 (-1.66%) CMC Crypto 200
1,299.31 -65.82 (-4.82%)
LYEL Oct 2024 2.500 call
| Previous close | 0.6000 |
| Open | 0.6000 |
| Bid | 0.3000 |
| Ask | 0.9000 |
| Strike | 2.50 |
| Expiry date | 2024-10-18 |
| Day's range | 0.6000 - 0.6000 |
| Contract range | N/A |
| Volume | |
| Open interest | 140 |
GlobeNewswireLyell Immunopharma to Participate in BofA Securities Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the BofA Securities 2024 Health Care Conference on Tuesday, May 14 at 8:40 am PT. A live webcast of the presentation can be accessed through the Investors section of the Company's website at ww
Simply Wall St.Lyell Immunopharma First Quarter 2024 Earnings: US$0.24 loss per share (vs US$0.27 loss in 1Q 2023)
Lyell Immunopharma ( NASDAQ:LYEL ) First Quarter 2024 Results Key Financial Results Net loss: US$60.7m (loss narrowed...
- GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
Expect to share initial clinical and translational data from the Phase 1 trial of LYL797, a ROR1-targeted CAR T‑cell product candidate, this quarterOn track to report initial clinical data from the Phase 1 trial of LYL845, an epigenetically enhanced TIL product candidate, in the second half of 2024IND for second generation ROR1-targeted CAR T-cell product candidate on track for submission this quarterCash, cash equivalents and marketable securities of $526.3 million as of March 31, 2024 supports
